AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$BCAB

BioAtla, Inc.

Price · $BCABvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $BCAB in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $BCAB in the last 30 days.

Top stories · $BCABMore →
APR 1·National TodayLow

BioAtla Announces 50-for-1 Share Consolidation

BioAtla, Inc. announced a 50-for-1 share consolidation of its common stock to increase its per-share trading price and regain compliance with Nasdaq's $1.00 minimum bid price requirement. This strategic move, effective April 6, 2026, aims to maintain the company's Nasdaq listing, which is crucial for accessing capital markets and funding ongoing research and development. Stockholders approved the consolidation on March 23, 2026, with fractional shares to be paid in cash.

MAR 24·Stock Titan

BioAtla (NASDAQ: BCAB) approves merger, 1-for-50 reverse split and 2026 executive retention bonuses

BioAtla (NASDAQ: BCAB) stockholders have approved an internal merger with its wholly-owned subsidiary, BA Merger Sub, Inc., which will include a 1-for-50 reverse stock split. Additionally, the company's board has approved 2026 cash retention bonuses for key executives, including the CFO, CMO, and CEO, tied to specific financial and capital-raising milestones, replacing a regular bonus plan and salary increases. This decision comes after no bonuses were earned in 2025 due to unmet financial and business objectives.

NOV 21·GlobeNewswire

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

SAN DIEGO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- BioAtla, Inc. ( Nasdaq: BCAB ) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ( CAB ) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into ...

News on $BCAB

All news →